News
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
Pharmaceutical Technology on MSN20h
‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback